# ApoPharma clinical trials: 23 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials with ApoPharma as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by ApoPharma: 23 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/apopharma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| January 14, 2019 | NCT03802916 | Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload | ApoPharma | Phase 2 | Completed | Iron Overload Due to Repeated Red Blood Cell Transfusions | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03802916) |
| April 5, 2016 | NCT02728843 | Study of Parkinson's Early Stage With Deferiprone | ApoPharma | Phase 2 | Completed | Parkinson's Disease | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02728843) |
| June 8, 2015 | NCT02465489 | Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers | ApoPharma | Phase 1 | Completed | Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02465489) |
| May 28, 2015 | NCT02456558 | Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects | ApoPharma | Phase 1 | Completed | Asymptomatic HIV Infection | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02456558) |
| May 14, 2015 | NCT02443545 | Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias | ApoPharma | Phase 4 | Terminated | Iron Overload, Sickle Cell Disease, Other Anemias | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02443545) |
| May 13, 2015 | NCT02442310 | Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers | ApoPharma | Phase 1 | Completed | Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02442310) |
| July 16, 2014 | NCT02191657 | Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects | ApoPharma | Phase 1 | Completed | HIV Infection | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02191657) |
| July 15, 2014 | NCT02189941 | Pilot Study of the Pharmacokinetic Profile of Deferiprone Sustained-Release Formulation in Healthy Volunteers | ApoPharma | Phase 1 | Completed | Healthy | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02189941) |
| June 26, 2014 | NCT02174848 | Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration | ApoPharma | Phase 3 | Completed | Pantothenate Kinase-Associated Neurodegeneration | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02174848) |
| January 22, 2014 | NCT02041299 | Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias | ApoPharma | Phase 4 | Terminated | Iron Overload, Sickle Cell Disease, Other Anemias | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02041299) |
| November 21, 2013 | NCT01989455 | A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers | ApoPharma | Phase 1 | Completed | Healthy Volunteers | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01989455) |
| May 23, 2013 | NCT01860703 | Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects | ApoPharma | Phase 4 | Completed | Prolonged QTc Interval | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01860703) |
| April 24, 2013 | NCT01838291 | Active Drug Surveillance Program of Ferriprox Use | ApoPharma | Observational | Completed | Transfusional Iron Overload | 294 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01838291) |
| April 19, 2013 | NCT01835496 | Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease | ApoPharma | Phase 1 | Completed | Sickle Cell Disease | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01835496) |
| January 18, 2013 | NCT01770652 | An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment | ApoPharma | Phase 4 | Completed | Renal Impairment | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01770652) |
| January 14, 2013 | NCT01767103 | An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers | ApoPharma | Phase 4 | Completed | Hepatic Impairment | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01767103) |
| December 5, 2012 | NCT01741532 | Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN) | ApoPharma | Phase 3 | Completed | Pantothenate Kinase-Associated Neurodegeneration | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01741532) |
| December 2, 2011 | NCT01483924 | Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis | ApoPharma | Phase 2 | Completed | Plaque Psoriasis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01483924) |
| May 12, 2009 | NCT00897221 | A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia | ApoPharma | Phase 2 | Completed | Friedreich's Ataxia | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00897221) |
| September 17, 2007 | NCT00530127 | A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia | ApoPharma | Phase 1/2 | Completed | Friedreich's Ataxia | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00530127) |
| September 14, 2007 | NCT00529152 | Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients | ApoPharma | Phase 3 | Completed | Iron Overload | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00529152) |
| October 12, 2006 | NCT00387101 | Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot Ulcers | ApoPharma | Phase 3 | Terminated | Diabetic Foot Ulcer | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00387101) |
| March 16, 2005 | NCT00105495 | Efficacy Study in Removing Excess Iron From the Heart | ApoPharma | Phase 4 | Completed | Thalassemia Major, Hemosiderosis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00105495) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 7 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 3 | 4 |
| Phase 4 | 6 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |
| Terminated | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Iron Overload | 6 |
| Anemia, Sickle Cell | 3 |
| Friedreich Ataxia | 2 |
| Pantothenate Kinase-Associated Neurodegeneration | 2 |
| HIV Infections | 2 |
| Liver Diseases | 1 |
| Parkinson Disease | 1 |
| Renal Insufficiency | 1 |
| Kidney Diseases | 1 |
| beta-Thalassemia | 1 |
| Hemosiderosis | 1 |
| Thalassemia | 1 |
| Hemochromatosis | 1 |
| Diabetic Foot | 1 |
| Diabetes Mellitus | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Steakhouses in the United States](https://specstream.ai/data/businesses/steakhouses/united-states)
- [Manufacturing consultants in the United States](https://specstream.ai/data/businesses/manufacturing-consultants/united-states)
- [Drywall contractors in the United States](https://specstream.ai/data/businesses/drywall-contractors/united-states)
- [Air duct cleaning companies in the United States](https://specstream.ai/data/businesses/air-duct-cleaning-companies/united-states)
- [Prenatal and perinatal care clinics in the United States](https://specstream.ai/data/businesses/prenatal-and-perinatal-care-clinics/united-states)
- [Hepatology practices in the United States](https://specstream.ai/data/businesses/hepatology-practices/united-states)
